Hedge Funds Are Betting On Bellicum Pharmaceuticals Inc (BLCM)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Bellicum Pharmaceuticals Inc (BLCM)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Long Focus Capital Management John B. Helmers | 0 | $0 | 0% | |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 0 | $0 | 0% | |
| 3. | Ikarian Capital Neil Shahrestani | 0 | $0 | 0% | |
| 4. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.00 | 5,000 | $19,998.50 | 5,000 | 2020-03-17 | Filing | |
| $1.25 | 40,000 | $50,000.00 | 66,561 | 2019-09-10 | Filing | |
| $1.23 | 8,000 | $9,821.60 | 18,294 | 2019-08-29 | Filing | |
| $0.99 | 20,000 | $19,780.00 | 26,561 | 2019-08-21 | Filing | |
| $4.56 | 10,000 | $45,600.00 | 10,000 | 2018-11-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.04 | 10,000 | $70,413.00 | 89,939 | 2018-09-04 | Filing | |
| $7.63 | 40,000 | $305,132.00 | 99,939 | 2018-07-18 | Filing | |
| $7.97 | 6,206 | $49,466.16 | 26,548 | 2018-05-25 | Filing | |
| $7.91 | 4,136 | $32,714.52 | 58,131 | 2018-01-19 | Filing | |
| $7.91 | 265,708 | $2,101,670.57 | 3,734,776 | 2018-01-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% |
News See All
13D Filing: Baker Bros. Advisors Owns 18% of Bellicum Pharmaceuticals, Inc (BLCM)
At Insider Monkey, we closely monitor the moves made by activist investors. Their targets are often undervalued stocks with firm foundations that for one reason or another have failed to execute.
A Look At Three Activist Moves By Several Elite Hedge Funds
According to the Schulte, Roth & Zabel’s Activist Investing 2015 Annual Review, 344 companies were targeted by activist investors in 2014, as compared with 291 recorded a year earlier.
Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals (BLCM): Redmile Group’s Top New Picks
Jeremy Green’s Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February.
Hedge Fund Resource Center